Want to see HK:1696 full AI Analyst Report?
1696 Stock Chart & Stats
HK$3.87
-HK$0.01(-0.28%)
At close: 4:00 PM EST
HK$3.87
-HK$0.01(-0.28%)
Day’s Range― - ―
52-Week RangeHK$2.10 - HK$8.07
Previous CloseN/A
Volume75.47K
Average Volume (3M)469.37K
Market Cap
HK$1.18B
Enterprise ValueHK$121.85M
Total Cash (Recent Filing)HK$70.96M
Total Debt (Recent Filing)HK$51.75M
Price to Earnings (P/E)7.9
Beta1.16
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.98%
Share Statistics
EPS (TTM)0.04
Shares Outstanding468,343,080
10 Day Avg. Volume515,040
30 Day Avg. Volume469,367
Financial Highlights & Ratios
PEG Ratio-0.55
Price to Book (P/B)0.53
Price to Sales (P/S)0.69
P/FCF Ratio37.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.52
Revenue Forecast (FY)HK$3.17B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and an expanding equity base provide durable financial flexibility. This reduces refinancing and solvency risk, supports continued R&D and service investments, and makes the company better able to absorb cyclical demand swings or fund targeted growth without forcing dilutive capital raises.
Installed-base Recurring RevenueA business model that pairs capital equipment with consumables and service creates steady, annuity-like revenue. Installed-base driven consumables and service contracts stabilize cash flows, improve lifetime customer value, and cushion capital-sales cyclicality, supporting long-term margin resilience.
High Gross Margin And Positive Revenue TrendA ~59% gross margin signals product-level pricing power and favorable unit economics that can support recovery in operating margins if sales mix improves. Coupled with multi-year revenue growth (albeit uneven), these structural metrics underpin sustainable profit potential as consumables and services scale.
Bears Say
Margin CompressionA pronounced fall from double-digit to low single-digit net margins indicates structural pressure from higher operating costs, pricing erosion, or adverse mix. This weakens return on capital, limits reinvestment capacity, and means management must restore operating leverage to sustain long-term profitability.
Weakened Cash GenerationSharp deterioration in OCF and FCF reduces internal funding for R&D, service expansion, and working capital, increasing reliance on external financing for growth or dividends. Low cash conversion versus revenue also raises sensitivity to working-capital swings and constrains strategic flexibility over the medium term.
Uneven Revenue And EPS WeaknessIrregular top-line performance plus a ~24% EPS decline signals underlying volatility in demand, pricing or cost control. Persistent inconsistency hampers reliable forecasting, complicates capacity planning and undermines confidence in sustained margin recovery absent clearer improvement in execution or market share trends.
Sisram Medical Ltd. News
1696 FAQ
What was Sisram Medical Ltd.’s price range in the past 12 months?
Sisram Medical Ltd. lowest stock price was HK$2.10 and its highest was HK$8.07 in the past 12 months.
What is Sisram Medical Ltd.’s market cap?
Sisram Medical Ltd.’s market cap is HK$1.18B.
When is Sisram Medical Ltd.’s upcoming earnings report date?
Sisram Medical Ltd.’s upcoming earnings report date is Aug 26, 2026 which is in 22 days.
How were Sisram Medical Ltd.’s earnings last quarter?
Sisram Medical Ltd. released its earnings results on Mar 23, 2026. The company reported HK$0.21 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.21.
Is Sisram Medical Ltd. overvalued?
According to Wall Street analysts Sisram Medical Ltd.’s price is currently Overvalued.
Does Sisram Medical Ltd. pay dividends?
Sisram Medical Ltd. pays a Annually dividend of HK$0.126 which represents an annual dividend yield of 4.98%. See more information on Sisram Medical Ltd. dividends here
What is Sisram Medical Ltd.’s EPS estimate?
Sisram Medical Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sisram Medical Ltd. have?
Sisram Medical Ltd. has 468,343,080 shares outstanding.
What happened to Sisram Medical Ltd.’s price movement after its last earnings report?
Sisram Medical Ltd. reported an EPS of HK$0.21 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -6.316%.
Which hedge fund is a major shareholder of Sisram Medical Ltd.?
Currently, no hedge funds are holding shares in HK:1696
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sisram Medical Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
26.21%
12-Months-Change
Fundamentals
Return on Equity
4.98%
Trailing 12-Months
Asset Growth
4.79%
Trailing 12-Months
Company Description
Sisram Medical Ltd.
Sisram Medical Ltd, an investment holding company headquartered in Caesarea, Israel, since its establishment in 2013, is engaged in the creation, production, and worldwide distribution of a broad spectrum of medical solutions. The company develops and markets energy-based aesthetic devices, minimally invasive therapeutic systems, non-energy-dependent equipment, and cosmeceuticals, reaching markets across Asia Pacific, Europe, North America, Latin America, the Middle East, and Africa. Its comprehensive range of products and treatments addresses numerous conditions, such as hair removal, skin revitalization, acne and scarring, body and facial sculpting, pigment and skin surface refinement, fat transfer procedures, injectable dermal fillers, skin tissue regeneration injectables, personal wellness items, cosmetic dental procedures, transdermal delivery methods, cellulite reduction, stretch mark amelioration, therapy for vascular and pigmented lesions, hydradermabrasion, non-surgical eyelid lifts (blepharoplasty), liposuction, as well as feminine health and sexual well-being applications. Furthermore, the company is involved in the manufacturing, distribution, and sales of general medical apparatus. Sisram Medical's offerings are available under its prominent brand names, which include Alma, Soprano, Harmony, Copulla, Foshion, Accent, and LMNT.
Technical Analysis
Peijia Medical Ltd.
―
Yestar Healthcare Holdings Co Ltd
―
Gaush Meditech Ltd.
―
Venus Medtech (Hangzhou), Inc. Class H
―
Austar Lifesciences Ltd.
―